{"id":"NCT03067129","sponsor":"AbbVie","briefTitle":"A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection","officialTitle":"An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2017-03-20","primaryCompletion":"2020-05-21","completion":"2022-09-12","firstPosted":"2017-03-01","resultsPosted":"2021-07-13","lastUpdate":"2023-05-09"},"enrollment":129,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus (HCV)"],"interventions":[{"type":"DRUG","name":"Glecaprevir/Pibrentasvir Adult Formulation","otherNames":["ABT-493/ABT-530","MAVYRETÂ®"]},{"type":"DRUG","name":"Glecaprevir + Pibrentasvir Pediatric Formulation","otherNames":["ABT-493/ABT-530"]}],"arms":[{"label":"Cohort 1: Adult Formulation; 12 to < 18 years","type":"EXPERIMENTAL"},{"label":"Cohort 2: Pediatric Formulation; 9 to < 12 years","type":"EXPERIMENTAL"},{"label":"Cohort 3: Pediatric Formulation; 6 to < 9 years","type":"EXPERIMENTAL"},{"label":"Cohort 4: Pediatric Formulation; 3 to < 6 years","type":"EXPERIMENTAL"}],"summary":"The objectives of this study are to assess the pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir adult formulation in adolescents ages 12 to 17 years and a pediatric formulation of glecaprevir and pibrentasvir in children ages 3 to \\< 12 years.","primaryOutcome":{"measure":"Steady-state Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours Postdose (AUC0-24) of Glecaprevir","timeFrame":"Week 2 from predose to 24 hours post-dose","effectByArm":[{"arm":"Cohort 1: Adult Formulation GLE/PIB; 12 to < 18 Years","deltaMin":4790,"sd":null},{"arm":"Cohort 2: Pediatric Formulation GLE + PIB; 9 to < 12 Years","deltaMin":7870,"sd":null},{"arm":"Cohort 3: Pediatric Formulation GLE + PIB; 6 to < 9 Years","deltaMin":6860,"sd":null},{"arm":"Cohort 4: Pediatric Formulation GLE + PIB; 3 to < 6 Years","deltaMin":7520,"sd":null}],"pValues":[]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":38,"countries":["United States","Belgium","Canada","Germany","Japan","Puerto Rico","Russia","Spain","United Kingdom"]},"refs":{"pmids":["33811356","31254392"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":47},"commonTop":["HEADACHE","VOMITING","NASOPHARYNGITIS","UPPER RESPIRATORY TRACT INFECTION","FATIGUE"]}}